Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)Paolo Bonfanti, Lucia Taramasso, Paola Tatarelli et al.|BMC Infectious Diseases|2018Cited by 63
Efficacy of bezlotoxumab in preventing the recurrence of Clostridioides difficile infection: an Italian multicenter cohort studyMarianna Meschiari, Cristina Mussini, Guido Granata et al.|International Journal of Infectious Diseases|2023Cited by 8